Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the colon metastatic to the liver that expresses carcinoembryonic antigen (CEA) after resection with curative intent * At least 50% of the tumor cells must stain positive for CEA with at least moderate intensity * No gross residual disease after surgery PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 70-100% Life expectancy: * Greater than 6 months Hematopoietic: * Absolute neutrophil count at least 1000/mm 3 * Hemoglobin at least 9 g/dL * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin less than 2.0 mg/dL * No chronic or acute hepatic disease Renal: * Creatinine less than 2.5 mg/dL Cardiovascular: * No chronic or acute cardiac disease (New York Heart Association class III or IV) Pulmonary: * No chronic or acute pulmonary illness such as asthma or chronic obstructive pulmonary disease Other: * Not pregnant or nursing * No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years * No history of autoimmune disease such as inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, and multiple sclerosis * No active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis * No active infectious enteritis or eosinophilic enteritis PRIOR CONCURRENT THERAPY: Biologic therapy: * No other concurrent immunotherapy Chemotherapy: * No concurrent chemotherapy * At least 6 weeks since prior chemotherapy Endocrine therapy: * No concurrent steroid therapy (or any other immunosuppressives) * At least 6 weeks since prior steroid therapy Radiotherapy: * No concurrent radiotherapy * At least 6 weeks since prior radiotherapy Surgery: * Recovered from prior surgery